Brief: Chiome Bioscience says receipt of formal notification associated with option license agreements of LIV-1205 and LIV-2008b
26/06/2017 07:47
June 26 (Reuters) - Chiome Bioscience Inc 4583.T
* Says co receives two formal notifications from ADC
Therapeutics SA in respect of LIV-1205 and LIV-2008b
* In regard to LIV-1205, co grants ADC Therapeutics SA
exclusive rights of development, manufacture and sales of
LIV-1205 Antibody Drug Conjugate (ADC)
* Says co will receive an undisclosed up-front payment
following execution of the definitive license agreement for
LIV-1205
* In regard to LIV-2008b, ADC Therapeutics has advised it
will not exercise the option to develop an ADC and co will
continue to make efforts to develop and outlicense thereafter
Source text in Japanese: https://goo.gl/6qZykA
Further company coverage: 4583.T
(Beijing Headline News)
((Beijing.HeadlineNews@thomsonreuters.com; +86 010 62674724;
Reuters Messaging: Tingting.liu@thomsonreuters.com@reuters.net))